Floatz logo

Telaglenastat

Acute Myeloid Leukemia With Multilineage Dysplasia

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Acute Myeloid Leukemia With Multilineage Dysplasia cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
Institut de Recherches Internationales Servier
Phase 2BB
Daunorubicin
Institut de Recherches Internationales Servier
Phase 3BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

Telaglenastat is also rated in:

Metastatic Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →